Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,374 across all filing types
Latest filing 2021-02-02 Share Issue/Capital Cha…
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
Monthly Returns
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/01/2021, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions. The content focuses on changes in share capital and securities issued during the month, which aligns with disclosures about share capital changes rather than financial performance or management commentary. There is no indication of financial statements, earnings data, or management discussion. The document is a regulatory disclosure about share capital movements, which fits the category of Share Issue/Capital Change (SHA). The document length is substantial and contains detailed data, so it is not merely an announcement of a report but the report itself on share capital movements.
2021-02-02 English
ANNOUNCEMENT ON THE UNAUDITED MAJOR OPERATIONAL DATA OF THE FOURTH QUARTER OF 2020
Regulatory Filings Classification · 90% confidence The document is an announcement from Yanzhou Coal Mining Company Limited regarding unaudited major operational data for the fourth quarter of 2020. It contains specific operational metrics such as production and sales volumes for coal and coal chemicals, but it explicitly states that the data is unaudited and is a voluntary announcement. The document is relatively short (3931 characters) and does not contain comprehensive financial statements or detailed financial analysis typical of interim or annual reports. It also does not present itself as a full financial report but rather as an operational data update. There is no indication that this is a full quarterly or interim report (IR), nor is it an earnings release (ER) which typically highlights key financial results. Given the nature of the content and length, this fits best as a Regulatory Filing (RNS) because it is a regulatory announcement of operational data without full financial statements or audit. Therefore, the classification is RNS with high confidence.
2021-01-29 English
VOLUNTARY ANNOUNCEMENT - CSTONE REPORTS EFFICACY AND SAFETY DATA FROM THE ARROW TRIAL OF PRALSETINIB IN CHINESE PATIENTS WITH ADVANCED RET FUSION-POSITIVE NSCLC AFTER PLATINUM-BASED CHEMOTHERAPY AT IA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CStone Pharmaceuticals reporting clinical trial results from the ARROW trial of pralsetinib in Chinese patients with RET fusion-positive NSCLC. It includes detailed efficacy and safety data, statements from investigators, and information about the drug and company. The document is not a full financial report, audit, or regulatory filing. It is not a transcript, capital update, or management change announcement. It is a clinical trial results announcement, which is typically categorized as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit into other specific financial or corporate filing categories. The document length is over 10,000 characters, indicating it is not a brief report publication announcement. Therefore, the best classification is Regulatory Filings (RNS).
2021-01-28 English
RESIGNATION OF COMPANY SECRETARY, APPOINTMENT OF JOINT COMPANY SECRETARIES AND CHANGE IN AUTHORIZED REPRESENTATIVES
Board/Management Information Classification · 100% confidence The document is an announcement from CStone Pharmaceuticals regarding the resignation of the company secretary, appointment of joint company secretaries, and changes in authorized representatives. It details personnel changes at the board/management level, including biographical information about the new appointees and a waiver from compliance with certain listing rules. There is no financial data, earnings information, or report publication mentioned. The content focuses on management and board changes, which fits the category of Board/Management Information (MANG). The document length is 6575 characters, which is sufficient for a detailed announcement but does not constitute a full report like an annual or interim report.
2021-01-25 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Report Publication Announcement Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2021-01-22 English
PUBLICATION OF THE PRODUCTION AND SALES VOLUME FOR THE FOURTH QUARTER OF 2020 OF AN OVERSEAS SUBSIDIARY CONTROLLED BY YANZHOU COAL MINING COMPANY LIMITED
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Yanzhou Coal Mining Company Limited regarding the production and sales volume for the fourth quarter of 2020 of an overseas subsidiary, Yancoal Australia. It provides summary data on coal production and sales volumes but does not contain detailed financial statements or comprehensive analysis. The document is relatively short (2470 characters) and refers readers to the full reports published by Yancoal Australia on the ASX and HKEX websites for further details. This indicates that the document is an announcement of operational data rather than a full financial report or detailed investor presentation. It is not an earnings release since it lacks key financial highlights or earnings figures, nor is it a regulatory filing or certification. Given the nature and length, this fits best as a Regulatory Filing (RNS) which serves as a general announcement category for miscellaneous filings that do not fit other specific categories.
2021-01-19 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.